Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 4/2012

01.08.2012 | Review

The interaction between ER and NFκB in resistance to endocrine therapy

verfasst von: Leen Sas, Filip Lardon, Peter B Vermeulen, Jan Hauspy, Peter Van Dam, Patrick Pauwels, Luc Y Dirix, Steven J Van Laere

Erschienen in: Breast Cancer Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Endocrine therapy is a commonly used treatment for estrogen receptor (ER)-positive breast cancer. Although endocrine therapy has a favorable outcome in many patients, development of resistance is common. Recent studies have shown that NFκB, a transcription factor regulating a wide variety of cellular processes, might play a role in the development of endocrine resistance. The precise interaction between ER and NFκB and how this contributes to the attenuated responsiveness of ER-positive breast cancer cells to hormonal treatment remains unclear. This review provides an overview of the mechanisms of action for both transcription factors and focuses on the current knowledge explaining how ER and NFκB affect each other's activity and how this cross-talk might contribute to the development of an endocrine resistance phenotype in breast cancer cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
2.
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010, 107: 6994-6999. 10.1073/pnas.0912708107.CrossRefPubMedPubMedCentral
3.
4.
5.
Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007, 12: 631-663. 10.1634/theoncologist.12-6-631.CrossRefPubMed
6.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed
7.
Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006, 66: 3903-3911. 10.1158/0008-5472.CAN-05-4363.CrossRefPubMed
8.
Creighton CJ: A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007, 26: 4648-4655. 10.1038/sj.onc.1210245.CrossRefPubMed
9.
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signalling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68: 826-833. 10.1158/0008-5472.CAN-07-2707.CrossRefPubMed
10.
Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S: Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J Mol Endocrinol. 2008, 40: 173-184. 10.1677/JME-07-0165.CrossRefPubMedPubMedCentral
11.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or HER2 overexpression and MAPK hyperactivation. Br J Cancer. 2007, 97: 659-669. 10.1038/sj.bjc.6603906.CrossRefPubMedPubMedCentral
12.
Biswas DK, Cruz AP, Gansberger E, Pardee AB: Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. 2000, 97: 8542-8547. 10.1073/pnas.97.15.8542.CrossRefPubMedPubMedCentral
13.
Muramatsu M, Inoue S: Estrogen receptors: how do they control reproductive and nonreproductive functions?. Biochem Biophys Res Commun. 2000, 270: 1-10. 10.1006/bbrc.2000.2214.CrossRefPubMed
14.
Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM: Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 2004, 5: 174-181. 10.1016/S1470-2045(04)01413-5.CrossRefPubMed
15.
Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hERβ) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998, 243: 122-126. 10.1006/bbrc.1997.7893.CrossRefPubMed
16.
Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N, Yamaguchi Y: The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer. 2003, 10: 193-202. 10.1677/erc.0.0100193.CrossRefPubMed
17.
Barone I, Brusco L, Fuqua SA: Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010, 16: 2702-2708. 10.1158/1078-0432.CCR-09-1753.CrossRefPubMedPubMedCentral
18.
Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 1992, 89: 4037-4041. 10.1073/pnas.89.9.4037.CrossRefPubMedPubMedCentral
19.
Jordan VC: Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004, 5: 207-213. 10.1016/S1535-6108(04)00059-5.CrossRefPubMed
20.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003, 349: 1793-1802. 10.1056/NEJMoa032312.CrossRefPubMed
21.
Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001, 19: 881-894.PubMed
22.
Ring A, Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004, 11: 643-658. 10.1677/erc.1.00776.CrossRefPubMed
23.
Musgrove AE, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.CrossRefPubMed
24.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70: 2085-2094. 10.1158/0008-5472.CAN-09-3746.CrossRefPubMedPubMedCentral
25.
Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S99-S111.CrossRefPubMed
26.
Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA: Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene. 2010, 29: 6071-6083. 10.1038/onc.2010.333.CrossRefPubMed
27.
Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008, 29: 217-233.CrossRefPubMedPubMedCentral
28.
Johnston SR: Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer. 2009, 9 (Suppl 1): S28-S36.CrossRefPubMed
29.
Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003, 9 (Suppl 2): 447S-454S.PubMed
30.
Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I: Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003, 9: 1259-1266.PubMed
31.
Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H: Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on Relapse. Chin Med J. 2009, 122: 1764-1768.PubMed
32.
deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR: NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 2004, 15: 885-890. 10.1093/annonc/mdh232.CrossRefPubMed
33.
Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC: The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl31): 37-46.CrossRef
34.
Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC: Enhanced NF B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 2007, 7: 59-74. 10.1186/1471-2407-7-59.CrossRefPubMedPubMedCentral
35.
36.
Karin M: How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene. 1999, 18: 6867-6874. 10.1038/sj.onc.1203219.CrossRefPubMed
37.
Hoffmann A, Leung TH, Baltimore D: Genetic analysis of NF-κB/Rel transcription factors defines functional specificities. EMBO J. 2003, 22: 5530-5539. 10.1093/emboj/cdg534.CrossRefPubMedPubMedCentral
38.
Chen LF, Greene WC: Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol. 2004, 5: 392-401. 10.1038/nrm1368.CrossRefPubMed
39.
Sun SC: Non-canonical NF-κB signaling pathway. Cell Res. 2011, 21: 71-85. 10.1038/cr.2010.177.CrossRefPubMed
40.
Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY: Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci. 2010, 86: 199-206. 10.1016/j.lfs.2009.12.003.CrossRefPubMed
41.
42.
Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012, 12: 121-132.PubMed
43.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
44.
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009, 15: 416-428. 10.1016/j.ccr.2009.03.016.CrossRefPubMedPubMedCentral
45.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral
46.
Iliopoulos D, Hirsch HA, Struhl K: An epigenetic switch involving NF- B, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009, 139: 693-706. 10.1016/j.cell.2009.10.014.CrossRefPubMedPubMedCentral
47.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: Nuclear factor-κB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-κB DNA-binding. Clin Cancer Res. 2006, 12: 3249-3256. 10.1158/1078-0432.CCR-05-2800.CrossRefPubMed
48.
Van Laere S, Limame R, Van Marck EA, Vermeulen PB, Dirix LY: Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer. 2010, 116 (Suppl 11): 2794-2805.CrossRefPubMed
49.
Wu L, Shao L, An N, Wang J, Pazhanisamy S, Feng W, Hauer-Jensen M, Miyamoto S, Zhou D: IKKβ regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One. 2011, 6: e18447-10.1371/journal.pone.0018447.CrossRefPubMedPubMedCentral
50.
Belguise K, Sonenshein GE: PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis. J Clin Invest. 2007, 117: 4009-4021.PubMedPubMedCentral
51.
Ghisletti S, Meda C, Maggi A, Vegeto E: 17β-Estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. Mol Cell Biol. 2005, 25: 2957-2968. 10.1128/MCB.25.8.2957-2968.2005.CrossRefPubMedPubMedCentral
52.
Galien R, Garcia T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site. Nucleic Acids Res. 1997, 25: 2424-2429. 10.1093/nar/25.12.2424.CrossRefPubMedPubMedCentral
53.
Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL: CBP is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor. Mol Endocrinol. 2008, 22: 263-272.CrossRefPubMed
54.
Paimela T, Ryhänen T, Mannermaa E, Ojala J, Kalesnykas G, Salminen A, Kaarniranta K: The effect of 17β-estradiol on IL-6 secretion and NF-κB DNA-binding activity in human retinal pigment epithelial cells. Immunol Lett. 2007, 110: 139-144. 10.1016/j.imlet.2007.04.008.CrossRefPubMed
55.
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM: Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007, 12: 115-130. 10.1016/j.ccr.2007.07.004.CrossRefPubMedPubMedCentral
56.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370.CrossRefPubMedPubMedCentral
57.
Qiu J, Wang X, Guo X, Zhao C, Wu X, Zhang Y: Toll-like receptor 9 agonist inhibits ERa-mediated transactivation by activating NF-κB in breast cancer cell lines. Oncol Rep. 2009, 22: 935-941.CrossRefPubMed
58.
Hsu SM, Chen YC, Jiang MC: 17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear factor-kappa B activation by increasing nuclear factor-kappa B p105 level in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2000, 279: 47-52. 10.1006/bbrc.2000.3891.CrossRefPubMed
59.
Dai R, Phillips RA, Ahmed SA: Despite inhibition of nuclear localization of NF-κB p65, c-rel, and RelB, 17-β estradiol up-regulates NF-κB signalling in mouse splenocytes: the potential role of Bcl-3. J Immunol. 2007, 179: 1776-1783.CrossRefPubMed
60.
Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC: Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell. 2006, 21: 555-564. 10.1016/j.molcel.2006.01.014.CrossRefPubMed
61.
Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol. 2007, 9: 470-478. 10.1038/ncb1559.CrossRefPubMedPubMedCentral
62.
Acharyya S, Sharma SM, Cheng AS, Ladner KJ, He W, Kline W, Wang H, Ostrowski MC, Huang TH, Guttridge DC: TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in Duchenne muscular dystrophy. PLoS One. 2010, 5: e12479-10.1371/journal.pone.0012479.CrossRefPubMedPubMedCentral
63.
Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EM: Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011, 125: 387-394. 10.1007/s10549-010-0836-9.CrossRefPubMed
64.
Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE: RelB NF-κB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol. 2009, 29: 3832-3834. 10.1128/MCB.00032-09.CrossRefPubMedPubMedCentral
65.
Pradhan M, Bembinster LA, Baumgarten SC, Frasor J: Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF-κB cooperativity at adjacent response elements. J Biol Chem. 2010, 285: 31100-31106. 10.1074/jbc.M110.155309.CrossRefPubMedPubMedCentral
66.
Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A: Positive cross-talk between estrogen receptor and NF-κB in breast cancer. Cancer Res. 2009, 69: 8918-8925. 10.1158/0008-5472.CAN-09-2608.CrossRefPubMedPubMedCentral
67.
Frasor J, Weaver AE, Pradhan M, Mehta K: Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17β-estradiol and proinflammatory cytokines. Endocrinology. 2008, 149: 6272-6279. 10.1210/en.2008-0352.CrossRefPubMed
68.
Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE, Costas MA: TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumour cells through a complex containing nuclear factor-κB. Oncogene. 2006, 25: 1367-1377. 10.1038/sj.onc.1209176.CrossRefPubMed
69.
Daosukho C, Kiningham K, Kasarskis EJ, Ittarat W, St Clair DK: Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-κB dimerization. Oncogene. 2002, 21: 3603-3610. 10.1038/sj.onc.1205448.CrossRefPubMed
70.
Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB: Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell. 2005, 18: 71-82. 10.1016/j.molcel.2005.03.006.CrossRefPubMed
71.
Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC: Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res. 2006, 66: 10162-10170. 10.1158/0008-5472.CAN-05-4111.CrossRefPubMed
72.
Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 2004, 15: 937-949. 10.1016/j.molcel.2004.08.019.CrossRefPubMed
73.
Tu Z, Prajapati S, Park KJ, Kelly NJ, Yamamoto Y, Gaynor RB: IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J Biol Chem. 2006, 281: 6699-6706. 10.1074/jbc.M512439200.CrossRefPubMed
74.
Kim MR, Choi HK, Cho KB, Kim HS, Kang KW: Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 2009, 100: 1834-1841. 10.1111/j.1349-7006.2009.01260.x.CrossRefPubMed
75.
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010, 28: 1287-1293. 10.1200/JCO.2009.25.7246.CrossRefPubMedPubMedCentral
76.
Shih VF, Tsui R, Caldwell A, Hoffmann A: A single NFκB system for both canonical and non-canonical signaling. Cell Res. 2011, 21: 86-102. 10.1038/cr.2010.161.CrossRefPubMed
77.
Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R: BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 2010, 24: 2040-2055. 10.1096/fj.09-138305.CrossRefPubMedPubMedCentral
78.
Riggins RB, Zwart A, Nehra R, Clarke R: The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2005, 4: 33-41.CrossRefPubMed
79.
Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, van de Velde H, Vinken P, Vermeulen PB, van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY: A phase II study of the combination of endocrine treatment and Bortezomib in patients with endocrine resistant metastatic breast cancer. Oncol Rep. 2011, 27: 657-663.PubMed
Metadaten
Titel
The interaction between ER and NFκB in resistance to endocrine therapy
verfasst von
Leen Sas
Filip Lardon
Peter B Vermeulen
Jan Hauspy
Peter Van Dam
Patrick Pauwels
Luc Y Dirix
Steven J Van Laere
Publikationsdatum
01.08.2012
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 4/2012
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3196

Weitere Artikel der Ausgabe 4/2012

Breast Cancer Research 4/2012 Zur Ausgabe

Research article

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy

Research article

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

Review

ER and PR signaling nodes during mammary gland development

Research article

Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes

Meeting report

New methods in mammary gland development and cancer: proteomics, epigenetics, symmetric division and metastasis

Research article

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise